You are here: Industry Insights > Oncology

News List

Stemline Therapeutics Prices $45 Million Public Offering of Common Stock firstwordpharma
January 23, 2017
Stemline Therapeutics, Inc. (Nasdaq:STML) announced the pricing of an underwritten public offering of 4.5 million shares of its common stock at a price of $10.00 per share, with expected gross proceeds to Stemline of $45 million.
Ipsen to acquire oncology assets from Merrimack Pharmaceuticals cphi-online
January 18, 2017
Transaction includes US commercialization rights for Onivyde for metastatic pancreatic cancer in adult patients.
ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 fo firstwordpharma
January 18, 2017
ONCURIOUS NV announces that the European Commission has confirmed the orphan drug designation for TB-403 for medulloblastoma. Today's decision by the EC follows the earlier positive opinion issued by the European Medicine Agency (EMA).
Aptevo Spin-off Receives $20M Emergent Payment contractpharma
January 16, 2017
Final payment funds newly-launched oncology and hematology-focused company
Merck Licenses four oncology R&D programs from Vertex cphi-online
January 16, 2017
All programs (two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs) have first-in-class and best-in-class potential.
Philips, Illumina partner to offer integrated genomics solutions for oncology firstwordpharma
January 11, 2017
Philips and Illumina announced that they will collaborate to leverage Illumina's sequencing technology and BaseSpace Sequence Hub with Philips' cloud-based IntelliSpace Genomics clinical informatics platform in a bid to advance cancer research.
Ipsen to acquire global oncology assets from Merrimack for $1.25bn pharmaceutical-technology
January 11, 2017
French pharmaceutical company Ipsen has signed an agreement to acquire global oncology assets from US-based Merrimack Pharmaceuticals for $1.25bn.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 18 19 Next page